(NYSE American: VNRX) Takes Control Of Tuesday's Top Watchlist Spot (5 Key Potential Catalysts On Radar)

In the world of epigenetics, a once-quiet company is

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (NYSE American: VNRX) Takes Control Of Tuesday's Top Watchlist Spot (5 Key Potential Catalysts On Radar) *Click Here To Get Our Alerts Faster Via SMS* February 10th Greetings Readers, In the world of epigenetics, a once-quiet company is starting to make some noise. Using advanced molecular science, the company is creating new diagnostic tools that could redefine how doctors detect and track serious diseases. Its profile may be modest next to the industry’s bigger names, but the potential impact of its research is anything but small. With several new studies in motion and growing traction in regulatory markets around the world, the company’s steady rise points toward an emerging role in the future of simple, noninvasive disease testing. And with an analyst target pointing to potential triple-digit upside, and a mutliple technicals suggesting oversold conditions at close yesterday, this little-known NYSE American profile is topping our watchlist Tuesday: VolitionRx Limited (NYSE American: VNRX) Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. And based on multiple potential catalysts, (NYSE American: VNRX) has taken over the top spot on our watchlist. Check them out: #1. A Significant Analyst Target ($2.50) May Signal Triple-Digit Potential Upside. #2. Reimbursement Will Be A Major Milestone Towards Commercialization And Licensing Of Nu.Q®. #3. Exciting Findings From A Key Clinical Study Could Create A Buzz-Filled Environment. #4. Two New Centralized Lab Providers Create Availability For Company's Vet Cancer Test. #5. A Major Breakthrough Announced In Nu.Q® Vet Cancer Test Clinical Data. But more on those in a second... Complete Company Overview - VolitionRx Limited Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also improve their quality of life. Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore. Early Diagnosis Saves Lives Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That’s the world Volition is trying to build by developing their innovative family of simple, easy to use, cost-effective tests. Their patented technologies use chromosomal structures such as nucleosomes and transcription factors as biomarkers in cancer and other diseases. All the tests in their portfolio detect various characteristic changes that occur from the earliest stages of disease, enabling early detection and potentially a better way to monitor disease progression and a patient’s response to treatment. Nu.Q® Technology. The Company's ground breaking nucleosome quantification technology is currently being used for cancer applications in veterinary medicine and they are continuing to expand their technology in human medicine through early clinical trials in cancer, sepsis and beyond. Commercialization Strategy Underlying principles: low capex, low opex business model focused on commercial partnerships and outlicensing R&D -- R&D conducted by Volition and its research partners -- Monetize IP through licensing agreements with: upfront payments, milestone payments, recurring revenue from sales of key components & royalties Licensing and partnering criteria: -- Broad geographic reach -- Large installed base -- Experience of tech transfer -- Regulatory and clinical affairs -- Large sales and marketing teams 2026: Targeting multiple licensing deals in the human space Pioneering Liquid Biopsy Solving the "Needle in a Haystack" Problem One of the primary hurdles in liquid biopsy is the difficulty of detecting rare circulating tumor DNA (ctDNA) amidst a sea of healthy DNA. In December 2025, VNRX announced a technological breakthrough involving its Nu.Q® Capture technology. The company achieved a 180-fold (18,000%) enrichment of tumor-derived DNA. This advancement significantly enhances the sensitivity of sequencing, potentially allowing for the detection of cancer at much earlier stages when treatment is most effective. Strategic Expansion into Acute Care Beyond chronic disease, VNRX is targeting the high-stakes environment of intensive care units. The company's Nu.Q® NETs assay has been included in a major real-world evaluation in France for the early detection of sepsis. Sepsis is a leading cause of hospital mortality, and the ability to quantify Neutrophil Extracellular Traps (NETs) could provide doctors with a critical tool to identify at-risk patients hours or even days earlier than current methods. Robust Intellectual Property and Pipeline The company’s growth is underpinned by an extensive patent portfolio covering its nucleosome detection methods. Financial and Operational Strength As of the third quarter 2025, VNRX reported a cash position of approx. $12.3Mn. The company has been disciplined in its capital allocation, focusing on high-value commercial partnerships and streamlining its manufacturing processes. The management team, led by CEO Cameron Reynolds, brings decades of experience in the biotechnology sector, specifically in bringing novel diagnostic tools to global markets. Grab Sources And More Here: VNRX Website. VNRX Presentation. ----- And as I mentioned earlier, (NYSE American: VNRX) has several potential catalysts of focus. Take a look: #1. VNRX Potential Catalyst - A Significant Analyst Target ($2.50) May Signal Triple-Digit Potential Upside. Recently, Zacks Small-Cap Research analyst, Steven Ralston, provided coverage on (NYSE American: VNRX) with a price target of $2.50. From Monday's closing valuation, this target suggests a potential upside of 875+%. Here's some report highlights: Outlook: Management’s primary operational goal for 2025 is (was) to secure multiple licensing agreements for human diagnostic applications. In September Volition entered into two such licensing agreements. The company’s 1st commercial order for Nu.Q Cancer assays was received in November. The key financial goal for 2025 is (was) to achieve cash neutrality on a full-year basis. In 3Q 2025, cash burn was reduced to 1.2Mn per month. Papers, posters, conference presentations, webinars etc. continue on a brisk pace. ----- #2. VNRX Potential Catalyst - Reimbursement Will Be A Major Milestone Towards Commercialization And Licensing Of Nu.Q®. VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The submission will be actively supported by the Hospices Civils de Lyon (HCL), France's second largest university hospital system, and will run in parallel with the previously announced process to achieve clinical certification of the test at HCL. Professor Léa Payen, Professor in Toxicology and Biochemistry, Claude Bernard University of Lyon I and Hospices Civils de Lyon, France commented: "We are keen to support the submission of Volition's reimbursement dossier for its Nu.Q® Cancer assays so that we can introduce the test into routine, reimbursed clinical practice in France, through our extensive hospital network, for lung cancer management as soon as possible, hopefully later this year." ... Mr. Gael Forterre, Chief Commercial Officer, Volition concluded: "We are honored to have the support of our long term collaborator, Hospices Civils de Lyon. Reimbursement is the next step on the path to the first use of Nu.Q® in clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives." "Reimbursement will be a major milestone for Volition in the commercialization and licensing of Nu.Q® in the human cancer field. Once achieved, we anticipate the introduction into routine clinical use in France by the fourth quarter, 2026." Read the full article here. ----- #3. VNRX Potential Catalyst - Exciting Findings From A Key Clinical Study Could Create A Buzz-Filled Environment. Volition Announces Data to Support Use of Nu.Q® NETs in New Indication Nu.Q® Biomarker Paper Available on MedRXIV HENDERSON, Nev., Jan. 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the release of a new clinical study demonstrating the use of its Nu.Q® NETs assay in patient management for a chronic disease, Hidradenitis Suppurativa (HS), a lifelong disease which affects approximately 1% of the world's population. The Nu.Q® NETs assay is CE-Marked to detect diseases associated with NETosis and is therefore approved and commercially available for clinical use in 27 European Union (EU) member states, the three European Economic Area (EEA) countries (Iceland, Liechtenstein, and Norway) and the U.K. Mr. Remi Rabeuf, VP Corporate Alliances and Strategic Partnership, Volition added: "We are excited to report the findings of this clinical study, which focused on a chronic disease, HS. It paves the way to improve a patient's management through a personalized medicine approach. This study, together with previously published evidence, demonstrates that Nu.Q® NETs should enable clinicians and researchers to anticipate disease, guide treatment decisions, and monitor patients over time, across both acute and chronic conditions. Nu.Q® NETs is a simple, low-cost, accessible test to detect diseases associated with NETosis. The market opp. for such indications is significant, with a Total Addressable Market of $3.8Bn..." ... Read the full article here. ----- #4. VNRX Potential Catalyst - Two New Centralized Lab Providers Create Availability For Company's Vet Cancer Test. Volition Continues to Extend Access to Nu.Q® Vet Cancer Test HENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test in the U.S. and Asia, further expanding access to its canine cancer early detection tool. Midwest Veterinary Laboratory, a full-service independent reference laboratory in the U.S., will be offering the Nu.Q® Vet Cancer test to its customers across all 50 states from February 2026. Bioguard, a global animal health diagnostics company is now offering the Nu.Q® Vet Cancer Test through it's Animal Health Diagnostic Center, the first certified ISO/IEC 17025 animal disease testing laboratory in Taiwan and China. Dr. Tom Butera, Chief Executive Officer, Volition Veterinary Diagnostics Development LLC commented: "We are delighted to extend the availability of our groundbreaking Nu.Q® technology in both the U.S. and Asia through these well established reference labs. By incorporating the Nu.Q® Canine Cancer Test into annual checkups or regular senior wellness exams, veterinarians can detect cancer earlier and help pet owners make timely, informed decisions about cancer care. The market opp. for Nu.Q® Vet is considerable, with the Total Addressable Market for Canine Screening approximately $100Mn for the U.S., Europe and Japan and would increase to a little under $150Mn with the addition of China." Read the full article here. ----- #5. VNRX Potential Catalyst - A Major Breakthrough Announced In Nu.Q® Vet Cancer Test Clinical Data. VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats Paves the Way for World's First Feline Liquid Biopsy Test for Cancer Detection HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas. This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine. Frédéric Wuilque, VP-Global Products, Volition commented: "Historically, cancer in cats has been notoriously difficult to diagnose early, often requiring invasive biopsies or expensive imaging after symptoms have already progressed. Veterinarians have been asking for a feline solution for years. Our mission is to make cancer screening a routine part of every pet's annual wellness check and following the successful international rollout of our canine cancer test, we have now demonstrated that our technology is also effective for cats. We look forward to completing product development and making the Nu.Q® Vet Feline Test available through our existing distribution networks including reference laboratories and point-of-care platforms." ... Read the full article here. ----- (NYSE American: VNRX) Recap - 5 Potential Catalysts On Watch #1. A Significant Analyst Target ($2.50) May Signal Triple-Digit Potential Upside. #2. Reimbursement Will Be A Major Milestone Towards Commercialization And Licensing Of Nu.Q®. #3. Exciting Findings From A Key Clinical Study Could Create A Buzz-Filled Environment. #4. Two New Centralized Lab Providers Create Availability For Company's Vet Cancer Test. #5. A Major Breakthrough Announced In Nu.Q® Vet Cancer Test Clinical Data. ----- We're officially kicking-off coverage on VolitionRx Limited (NYSE American: VNRX). Updates will head your way soon. Keep your eyes peeled. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 02/10/2026 and ending on 02/10/2026 to publicly disseminate information about (VNRX:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid thirty seven thousand five hundred USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (VNRX:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/vnrx-qzefx/#details

SWN Media | 160 W. Camino Real Unit 886 | Boca Raton, FL 33432 US Unsubscribe | Update Profile | Constant Contact Data Notice

A Strong Analyst Target Pins (NYSE American: VNRX) To Tuesday's Watchlist (5 Potential Catalysts)

In the world of epigenetics, a once-quiet company is starting to make some noise.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored A Strong Analyst Target Pins (NYSE American: VNRX) To Tuesday's Watchlist (5 Potential Catalysts) *Click Here To Get Our Alerts Faster Via SMS* February 10th Dear Reader, In the world of epigenetics, a once-quiet company is starting to make some noise. Using advanced molecular science, the company is creating new diagnostic tools that could redefine how doctors detect and track serious diseases. Its profile may be modest next to the industry’s bigger names, but the potential impact of its research is anything but small. With several new studies in motion and growing traction in regulatory markets around the world, the company’s steady rise points toward an emerging role in the future of simple, noninvasive disease testing. And with an analyst target pointing to potential triple-digit upside, and a mutliple technicals suggesting oversold conditions at close yesterday, this little-known NYSE American profile is topping our watchlist Tuesday: VolitionRx Limited (NYSE American: VNRX) Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. And based on multiple potential catalysts, (NYSE American: VNRX) has taken over the top spot on our watchlist. Check them out: #1. A Significant Analyst Target ($2.50) May Signal Triple-Digit Potential Upside. #2. Reimbursement Will Be A Major Milestone Towards Commercialization And Licensing Of Nu.Q®. #3. Exciting Findings From A Key Clinical Study Could Create A Buzz-Filled Environment. #4. Two New Centralized Lab Providers Create Availability For Company's Vet Cancer Test. #5. A Major Breakthrough Announced In Nu.Q® Vet Cancer Test Clinical Data. But more on those in a second... Complete Company Overview - VolitionRx Limited Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also improve their quality of life. Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore. Early Diagnosis Saves Lives Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That’s the world Volition is trying to build by developing their innovative family of simple, easy to use, cost-effective tests. Their patented technologies use chromosomal structures such as nucleosomes and transcription factors as biomarkers in cancer and other diseases. All the tests in their portfolio detect various characteristic changes that occur from the earliest stages of disease, enabling early detection and potentially a better way to monitor disease progression and a patient’s response to treatment. Nu.Q® Technology. The Company's ground breaking nucleosome quantification technology is currently being used for cancer applications in veterinary medicine and they are continuing to expand their technology in human medicine through early clinical trials in cancer, sepsis and beyond. Commercialization Strategy Underlying principles: low capex, low opex business model focused on commercial partnerships and outlicensing R&D -- R&D conducted by Volition and its research partners -- Monetize IP through licensing agreements with: upfront payments, milestone payments, recurring revenue from sales of key components & royalties Licensing and partnering criteria: -- Broad geographic reach -- Large installed base -- Experience of tech transfer -- Regulatory and clinical affairs -- Large sales and marketing teams 2026: Targeting multiple licensing deals in the human space Pioneering Liquid Biopsy Solving the "Needle in a Haystack" Problem One of the primary hurdles in liquid biopsy is the difficulty of detecting rare circulating tumor DNA (ctDNA) amidst a sea of healthy DNA. In December 2025, VNRX announced a technological breakthrough involving its Nu.Q® Capture technology. The company achieved a 180-fold (18,000%) enrichment of tumor-derived DNA. This advancement significantly enhances the sensitivity of sequencing, potentially allowing for the detection of cancer at much earlier stages when treatment is most effective. Strategic Expansion into Acute Care Beyond chronic disease, VNRX is targeting the high-stakes environment of intensive care units. The company's Nu.Q® NETs assay has been included in a major real-world evaluation in France for the early detection of sepsis. Sepsis is a leading cause of hospital mortality, and the ability to quantify Neutrophil Extracellular Traps (NETs) could provide doctors with a critical tool to identify at-risk patients hours or even days earlier than current methods. Robust Intellectual Property and Pipeline The company’s growth is underpinned by an extensive patent portfolio covering its nucleosome detection methods. Financial and Operational Strength As of the third quarter 2025, VNRX reported a cash position of approx. $12.3Mn. The company has been disciplined in its capital allocation, focusing on high-value commercial partnerships and streamlining its manufacturing processes. The management team, led by CEO Cameron Reynolds, brings decades of experience in the biotechnology sector, specifically in bringing novel diagnostic tools to global markets. Grab Sources And More Here: VNRX Website. VNRX Presentation. ----- And as I mentioned earlier, (NYSE American: VNRX) has several potential catalysts of focus. Take a look: #1. VNRX Potential Catalyst - A Significant Analyst Target ($2.50) May Signal Triple-Digit Potential Upside. Recently, Zacks Small-Cap Research analyst, Steven Ralston, provided coverage on (NYSE American: VNRX) with a price target of $2.50. From Monday's closing valuation, this target suggests a potential upside of 875+%. Here's some report highlights: Outlook: Management’s primary operational goal for 2025 is (was) to secure multiple licensing agreements for human diagnostic applications. In September Volition entered into two such licensing agreements. The company’s 1st commercial order for Nu.Q Cancer assays was received in November. The key financial goal for 2025 is (was) to achieve cash neutrality on a full-year basis. In 3Q 2025, cash burn was reduced to 1.2Mn per month. Papers, posters, conference presentations, webinars etc. continue on a brisk pace. ----- #2. VNRX Potential Catalyst - Reimbursement Will Be A Major Milestone Towards Commercialization And Licensing Of Nu.Q®. VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The submission will be actively supported by the Hospices Civils de Lyon (HCL), France's second largest university hospital system, and will run in parallel with the previously announced process to achieve clinical certification of the test at HCL. Professor Léa Payen, Professor in Toxicology and Biochemistry, Claude Bernard University of Lyon I and Hospices Civils de Lyon, France commented: "We are keen to support the submission of Volition's reimbursement dossier for its Nu.Q® Cancer assays so that we can introduce the test into routine, reimbursed clinical practice in France, through our extensive hospital network, for lung cancer management as soon as possible, hopefully later this year." ... Mr. Gael Forterre, Chief Commercial Officer, Volition concluded: "We are honored to have the support of our long term collaborator, Hospices Civils de Lyon. Reimbursement is the next step on the path to the first use of Nu.Q® in clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives." "Reimbursement will be a major milestone for Volition in the commercialization and licensing of Nu.Q® in the human cancer field. Once achieved, we anticipate the introduction into routine clinical use in France by the fourth quarter, 2026." Read the full article here. ----- #3. VNRX Potential Catalyst - Exciting Findings From A Key Clinical Study Could Create A Buzz-Filled Environment. Volition Announces Data to Support Use of Nu.Q® NETs in New Indication Nu.Q® Biomarker Paper Available on MedRXIV HENDERSON, Nev., Jan. 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the release of a new clinical study demonstrating the use of its Nu.Q® NETs assay in patient management for a chronic disease, Hidradenitis Suppurativa (HS), a lifelong disease which affects approximately 1% of the world's population. The Nu.Q® NETs assay is CE-Marked to detect diseases associated with NETosis and is therefore approved and commercially available for clinical use in 27 European Union (EU) member states, the three European Economic Area (EEA) countries (Iceland, Liechtenstein, and Norway) and the U.K. Mr. Remi Rabeuf, VP Corporate Alliances and Strategic Partnership, Volition added: "We are excited to report the findings of this clinical study, which focused on a chronic disease, HS. It paves the way to improve a patient's management through a personalized medicine approach. This study, together with previously published evidence, demonstrates that Nu.Q® NETs should enable clinicians and researchers to anticipate disease, guide treatment decisions, and monitor patients over time, across both acute and chronic conditions. Nu.Q® NETs is a simple, low-cost, accessible test to detect diseases associated with NETosis. The market opp. for such indications is significant, with a Total Addressable Market of $3.8Bn..." ... Read the full article here. ----- #4. VNRX Potential Catalyst - Two New Centralized Lab Providers Create Availability For Company's Vet Cancer Test. Volition Continues to Extend Access to Nu.Q® Vet Cancer Test HENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test in the U.S. and Asia, further expanding access to its canine cancer early detection tool. Midwest Veterinary Laboratory, a full-service independent reference laboratory in the U.S., will be offering the Nu.Q® Vet Cancer test to its customers across all 50 states from February 2026. Bioguard, a global animal health diagnostics company is now offering the Nu.Q® Vet Cancer Test through it's Animal Health Diagnostic Center, the first certified ISO/IEC 17025 animal disease testing laboratory in Taiwan and China. Dr. Tom Butera, Chief Executive Officer, Volition Veterinary Diagnostics Development LLC commented: "We are delighted to extend the availability of our groundbreaking Nu.Q® technology in both the U.S. and Asia through these well established reference labs. By incorporating the Nu.Q® Canine Cancer Test into annual checkups or regular senior wellness exams, veterinarians can detect cancer earlier and help pet owners make timely, informed decisions about cancer care. The market opp. for Nu.Q® Vet is considerable, with the Total Addressable Market for Canine Screening approximately $100Mn for the U.S., Europe and Japan and would increase to a little under $150Mn with the addition of China." Read the full article here. ----- #5. VNRX Potential Catalyst - A Major Breakthrough Announced In Nu.Q® Vet Cancer Test Clinical Data. VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats Paves the Way for World's First Feline Liquid Biopsy Test for Cancer Detection HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas. This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine. Frédéric Wuilque, VP-Global Products, Volition commented: "Historically, cancer in cats has been notoriously difficult to diagnose early, often requiring invasive biopsies or expensive imaging after symptoms have already progressed. Veterinarians have been asking for a feline solution for years. Our mission is to make cancer screening a routine part of every pet's annual wellness check and following the successful international rollout of our canine cancer test, we have now demonstrated that our technology is also effective for cats. We look forward to completing product development and making the Nu.Q® Vet Feline Test available through our existing distribution networks including reference laboratories and point-of-care platforms." ... Read the full article here. ----- (NYSE American: VNRX) Recap - 5 Potential Catalysts On Watch #1. A Significant Analyst Target ($2.50) May Signal Triple-Digit Potential Upside. #2. Reimbursement Will Be A Major Milestone Towards Commercialization And Licensing Of Nu.Q®. #3. Exciting Findings From A Key Clinical Study Could Create A Buzz-Filled Environment. #4. Two New Centralized Lab Providers Create Availability For Company's Vet Cancer Test. #5. A Major Breakthrough Announced In Nu.Q® Vet Cancer Test Clinical Data. ----- We're officially kicking-off coverage on VolitionRx Limited (NYSE American: VNRX). Updates will head your way soon. Keep your eyes peeled. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 02/10/2026 and ending on 02/10/2026 to publicly disseminate information about (VNRX:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid thirty seven thousand five hundred USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (VNRX:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/vnrx-qzefx/#details

Fierce Investor | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice